TNFRSF4 anticorps (N-Term)

N° du produit ABIN3029375

Détail du produit anti-TNFRSF4 anticorps

Antigène: TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))

Épitope: N-Term

Reactivité: Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TNFRSF4 est non-conjugé

Application: Western Blotting (WB)

Purification: Antigen affinity

Immunogène: An amino acid sequence from the N-terminus of rat CD134/OX40 (KLNCVKDTYPSGHKCCRECQ) was used as the immunogen for this OX40 antibody.

Isotype: IgG

Information d'application

Indications d'application: The stated application concentrations are suggested starting amounts. Titration of the OX40 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Restrictions: For Research Use only

Stockage

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Stock: -20 °C

Stockage commentaire: After reconstitution, the OX40 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Détails sur TNFRSF4

Antigène: TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))

Autre désignation: OX40 (TNFRSF4 Produits)

Synonymes: anticorps TNFRSF4, anticorps ACT35, anticorps CD134, anticorps Ly-70, anticorps Ox40, anticorps TXGP1L, anticorps Txgp1, anticorps OX40, anticorps TNF receptor superfamily member 4, anticorps tumor necrosis factor receptor superfamily, member 4, anticorps TNFRSF4, anticorps Tnfrsf4

Sujet: Tumor necrosis factor receptor superfamily, member4, also known as ACT35 or CD134 is a cell surface glycoprotein that was discovered through the production of a monoclonal antibody raised against the HUT-102 cell line. It belongs to the tumor necrosis factor receptor superfamily. CD134 was mapped to 1p36 by fluorescence in situ hybridization. CD134 is the primary receptor for feline immunodeficiency virus. CD134 expression can promote viral binding and renders cells permissive for viral entry, productive infection, and syncytium formation. Stimulating the receptor can improve the response to a powerful virus vector and may be useful in vaccine development.

UniProt: P15725

Pathways: Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints